Anti-RTVP-1 protein

The Uses of Anti-RTVP-1 protein

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit .

General Description

Glioma pathogenesis-related protein 1 (GLIPR1) is a multifunctional protein which was first recognized in human glioblastomas. It resides in endoplasmic reticulum (ER) and vesicles in cytoplasm. It is a transmembrane protein with its C-terminal spanning the membrane, and has a signal peptide at its N-terminal. It belongs to the CAP (cysteine-rich secretory proteins, antigen 5 and pathogenesis-related 1 proteins) family of proteins, and thus, contains the cysteine-rich CAP domain. GLIPR1 exists as three isoforms, namely, GLIPR1, GLIPR1-like 1 (GLIPR1L1) and GLIPR1-like 2 (GLIPR1L2). GLIPR1 and GLIPR1L2 have a wide range of tissue expression, whereas GLIPR1L1 is predominantly expressed in testis.

Biochem/physiol Actions

Glioma pathogenesis-related protein 1 (GLIPR1) is involved in cell cycle, tumorigenesis and apoptosis. It acts as an oncogene in glioblastoma and gliomas, and is overexpressed in the same. It is also unregulated in acute myeloid leukemia (AML), and may facilitate the proliferation of AML cells. Its expression levels are positively correlated with metastasis of tumors in case of astrocytic brain malignancies. Studies suggest that GLIPR1 acts as a tumor suppressor gene in prostate cancer, and its expression is suppressed in prostate cancer cells as compared to normal prostate cells. The expression of this gene is induced by the tumor suppressor gene p53 as well as DNA damage-causing substances such as irradiation. It is an HIV-1 dependency factor (HDF), and it is overexpressed during initial stages of HIV-1 (human immunodeficiency virus-1) infection.